Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr. Reddy's Laboratories Ltd    DRREDDY   INE089A01023

DR. REDDY'S LABORATORIES LTD (DRREDDY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Dr Reddy Laboratories : announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/14/2018 | 10:43am CEST

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced its intent to appeal the decision made by the U.S. District Court for the District of New Jersey in a preliminary injunction hearing with respect to further sales and commercialization of Dr. Reddy’s Buprenorphine and Naloxone Sublingual Film within the United States.

The company disagrees with the court’s decision, and will vigorously appeal it.

Dr. Reddy’s had announced the receipt of the approval, on June 15, 2018 by one of its wholly owned subsidiaries, from the U.S. Food and Drug Administration (USFDA) for its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, therapeutic equivalent generic version of Suboxone® (buprenorphine and naloxone) sublingual film, in the United States market.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR. REDDY'S LABORATORIES L
09/13DR REDDY LABORATORIES : Launches muscle disease drug
AQ
09/12DR REDDY LABORATORIES : Announces the Launch of Neostigmine Methylsulfate Inject..
BU
09/12DR REDDY LABORATORIES : announces the launch of Neostigmine Methylsulfate Inject..
PU
09/12INDIVIOR : Sublocade Uptake Picking Up
DJ
08/30CIPLA : Domestic pharma companies, baring vie for bharat serums & vaccines
AQ
08/25DR REDDY LABORATORIES : `s recalls Atorvastatin tablets in the US
AQ
08/24DR REDDY LABORATORIES : Srikakulam api unit gets usfda eir
AQ
08/23DR REDDY LABORATORIES : "Selectable Single Dose Auto-Injector And Methods Of Mak..
AQ
08/20DR REDDY LABORATORIES : Conversica Chief Scientist to Share AI Insights at Ventu..
AQ
08/14NATCO PHARMA : Dr Reddys eyeing European market for cancer drug
AQ
More news
News from SeekingAlpha
09/12Nostrum Labs hikes price of mature antibiotic 400% 
09/12Dr. Reddy's Laboratories launches Neostigmine Methylsulfate Injection, USP in.. 
08/08FDA OKs first generic drug under new accelerated pathway 
08/08Mylan's trimmed guidance may pressure generic drug makers 
07/30YOUR DAILY PHARMA SCOOP : ADMA Closer To PDUFA, Roche Proceeds, AstraZeneca Flun.. 
Financials (INR)
Sales 2019 157 B
EBIT 2019 19 041 M
Net income 2019 15 312 M
Debt 2019 28 258 M
Yield 2019 0,86%
P/E ratio 2019 27,56
P/E ratio 2020 20,24
EV / Sales 2019 2,88x
EV / Sales 2020 2,49x
Capitalization 424 B
Chart DR. REDDY'S LABORATORIES LTD
Duration : Period :
Dr. Reddy's Laboratories Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES L
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 38
Average target price 2 389  INR
Spread / Average Target -6,5%
EPS Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Erez Israeli Chief Operating Officer & Global Head-Generics
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR. REDDY'S LABORATORIES LTD6.73%5 880
JOHNSON & JOHNSON1.62%380 898
PFIZER21.65%256 467
NOVARTIS-0.56%216 108
ROCHE HOLDING LTD.-4.65%210 186
MERCK AND COMPANY25.79%188 241